Insights

Partnership Opportunities Recent partnerships with Vitalograph Inc and the AHSN Network indicate opportunities for collaboration in offering FeNO testing solutions to a wider patient base. Leveraging these partnerships can open doors for introducing NIOX VERO® to new healthcare facilities and networks.

Product Expansion The successful launch of DUAKLIR PRESSAIR for COPD treatment showcases NIOX Group's capabilities in developing innovative respiratory medical devices. This presents an avenue to explore cross-selling opportunities by introducing NIOX VERO® alongside DUAKLIR PRESSAIR for comprehensive respiratory health management.

Industry Leadership As a global leader in FeNO testing, NIOX Group plc holds a strong reputation for medical device innovation in asthma diagnosis. Leveraging this industry leadership can create sales opportunities by highlighting the superior performance and reliability of NIOX VERO® over competitors' products.

Networking Benefits NIOX Group's commitment to offering training and support for healthcare professionals presents a chance to engage with key opinion leaders and medical practitioners. Building relationships through networking events and training sessions can translate into sales opportunities by fostering trust and loyalty towards NIOX VERO®.

Financial Stability With a revenue of $10M - $50M and substantial funding of $98M, NIOX Group demonstrates financial stability and growth potential. Capitalizing on this financial health can lead to sales opportunities by assuring clients of the company's long-term commitment to product excellence and support services.

Similar companies to NIOX®

NIOX® Tech Stack

NIOX® uses 8 technology products and services including Google Hosted Libraries, WordPress, Floating UI, and more. Explore NIOX®'s tech stack below.

  • Google Hosted Libraries
    Content Delivery Network
  • WordPress
    Content Management System
  • Floating UI
    Javascript Libraries
  • jQuery Migrate
    Javascript Libraries
  • jQuery
    Javascript Libraries
  • SiteGround
    Platform As A Service
  • Animate.css
    UI Frameworks
  • Microsoft ASP.NET
    Web Frameworks

NIOX®'s Email Address Formats

NIOX® uses at least 2 format(s):
NIOX® Email FormatsExamplePercentage
First.Last@circassia.comJohn.Doe@circassia.com
85%
FirstLast@circassia.comJohnDoe@circassia.com
4%
First.Middle@circassia.comJohn.Michael@circassia.com
1%
First-Last@circassia.comJohn-Doe@circassia.com
2%
FiLast@circassia.comJoDoe@circassia.com
1%
First_Last@circassia.comJohn_Doe@circassia.com
1%
Last.First@circassia.comDoe.John@circassia.com
1%
LastFir@circassia.comDoeJoh@circassia.com
1%
FirstLa@circassia.comJohnDo@circassia.com
1%
F-Last@circassia.comJ-Doe@circassia.com
1%
Last.F@circassia.comDoe.J@circassia.com
1%
First@circassia.comJohn@circassia.com
1%
First.Last@niox.comJohn.Doe@niox.com
71%
FirLast@niox.comJohDoe@niox.com
17%
FiLast@niox.comJoDoe@niox.com
6%
FLast@niox.comJDoe@niox.com
6%

Frequently Asked Questions

Where is NIOX®'s headquarters located?

Minus sign iconPlus sign icon
NIOX®'s main headquarters is located at Edmund Halley Road Oxford, England OX4 4GB GB. The company has employees across 3 continents, including EuropeNorth AmericaAsia.

What is NIOX®'s phone number?

Minus sign iconPlus sign icon
You can contact NIOX®'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is NIOX®'s stock symbol?

Minus sign iconPlus sign icon
NIOX® is a publicly traded company; the company's stock symbol is CIR.L.

What is NIOX®'s official website and social media links?

Minus sign iconPlus sign icon
NIOX®'s official website is niox.com and has social profiles on LinkedIn.

How much revenue does NIOX® generate?

Minus sign iconPlus sign icon
As of May 2025, NIOX®'s annual revenue reached $35M.

What is NIOX®'s NAICS code?

Minus sign iconPlus sign icon
NIOX®'s NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does NIOX® have currently?

Minus sign iconPlus sign icon
As of May 2025, NIOX® has approximately 126 employees across 3 continents, including EuropeNorth AmericaAsia. Key team members include Chief Commercial Officer: R. Y.Head Of Marketing: S. I.Regional Vice President, Emea And Partner Markets: W. S.. Explore NIOX®'s employee directory with LeadIQ.

What industry does NIOX® belong to?

Minus sign iconPlus sign icon
NIOX® operates in the Medical Equipment Manufacturing industry.

What technology does NIOX® use?

Minus sign iconPlus sign icon
NIOX®'s tech stack includes Google Hosted LibrariesWordPressFloating UIjQuery MigratejQuerySiteGroundAnimate.cssMicrosoft ASP.NET.

What is NIOX®'s email format?

Minus sign iconPlus sign icon
NIOX®'s email format typically follows the pattern of . Find more NIOX® email formats with LeadIQ.

How much funding has NIOX® raised to date?

Minus sign iconPlus sign icon
As of May 2025, NIOX® has raised $98M in funding. The last funding round occurred on Apr 19, 2011 for $98M.

When was NIOX® founded?

Minus sign iconPlus sign icon
NIOX® was founded in 2006.
NIOX®

NIOX®

Medical Equipment ManufacturingEngland, United Kingdom51-200 Employees

NIOX Group plc is a company that specialises in the development, manufacture, and distribution of medical devices for the diagnosis and monitoring of asthma. Their flagship product, NIOX VERO®, is a non-invasive medical device that measures fractional exhaled nitric oxide (FeNO) levels in patients with asthma.

NIOX VERO® provides accurate and reliable results, allowing healthcare
professionals to make informed decisions about the diagnosis and management of asthma. It is easy to use, and can be used in a variety of settings, including clinics, hospitals, and primary care settings.

The NIOX Group plc is committed to improving the lives of people with asthma and is dedicated to innovation and excellence in its products and services. NIOX® is also committed to offering additional training and support for healthcare professionals.

Overall, NIOX Group plc is the global leader in FeNO testing, with a strong
reputation for innovation and excellence in the development of medical devices for the diagnosis and management of asthma. With NIOX VERO®, healthcare professionals have a reliable and non-invasive tool to help them better diagnose and manage asthma.

References:
1. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO®: randomized studies in asthma. Pulm Ther. 2017;3:207-218.
2. Gao J et al. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy, Asthma & Clinical Immunology. 2018;1
3. Busse WW et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021;9(10):1165-1173.
4. Menzies-Gow A et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633.
5. NIOX®. Data on File; MKT-DOF-007.

Section iconCompany Overview

Headquarters
Edmund Halley Road Oxford, England OX4 4GB GB
Phone number
Website
niox.com
Stock Symbol
CIR.L
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2006
Employees
51-200

Section iconFunding & Financials

  • $98M

    NIOX® has raised a total of $98M of funding over 4 rounds. Their latest funding round was raised on Apr 19, 2011 in the amount of $98M.

  • $10M$50M

    NIOX®'s revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $98M

    NIOX® has raised a total of $98M of funding over 4 rounds. Their latest funding round was raised on Apr 19, 2011 in the amount of $98M.

  • $10M$50M

    NIOX®'s revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.